Czechia medical psilocybin

1. Introduction

Version followed: Klinický doporučený postup pro asistovanou psychoterapii psilocybinem pro léčebné použití (PS ČLS JEP and ČNPS; authors Horáček, Páleníček, Tylš, Viktorin; published in Věstník MZd ČR, částka 21/2025; effective 1 January 2026), read together with Nařízení vlády č. 552/2025 Sb. and Act No. 167/1998 Sb. as amended by Act No. 270/2025 Sb. Legal and access status is given as of the sources' dates (latest: 30 September 2026).

This is a regulated-access programme, not a distinct psychotherapy school. Since 1 January 2026, Czech law lets an individually prepared medicinal product containing psilocybin be prescribed and given in authorised healthcare settings. It may be used only for defined severe conditions, only after registered treatments have failed or were not tolerated, and only as psilocybin-assisted psychotherapy (asistovaná psychoterapie psilocybinem, PAP) that follows the single national clinical guideline. [source: Věstník guideline; NV 552/2025 Sb.; epravo.cz commentary]

The guideline's account of change is brief. A non-directive accompanied altered state, prepared for within a strong therapeutic alliance and then integrated into the patient's clinical problem and attitudes, is expected to produce improvement in a treatment-resistant condition. The guideline names the alliance as the basic precondition for safety. [source: Věstník guideline §§ 8–10] Any fuller theory of change is not in the guideline and is not added here. [uncertain]

Legal basis and dates

• Act No. 270/2025 Sb. amended Act No. 167/1998 Sb. (on addictive substances), adding § 33l (therapeutic psilocybin under special supervision by a physician), and Act No. 378/2007 Sb. (medicines, § 79a). The same act also amended the Criminal Code. [source: NV 552/2025 Sb. preamble; epravo.cz] The government's drug-policy department reports that the Senate approved the government's Criminal Code amendment on 3 July 2025 (Senate print 143) and that it went to the President on 10 July 2025. That press release does not mention psilocybin, so linking it to Act 270/2025 is [uncertain].
• Consolidated Act 167/1998 Sb. (as of 1 January 2026, Ministry of Health / Ministerstvo zdravotnictví text): "psilocybin pro léčebné použití" is a defined term (§ 2). Use is permitted in psychiatric hospitals and psychiatric facilities directly managed by the Ministry, and in psychiatric outpatient, day or inpatient units of Ministry-run hospitals. Other facilities need a Ministry permit, which requires them to show they meet the conditions and to declare that a qualified supervising physician is present (§ 3(3), § 8(6)(k), § 8(14)). Only a psychiatrist, or a physician with the special qualification in medical psychotherapy, who carries out the special supervision may administer it. [source: MZd consolidated text] The full wording of § 33l is not drawn on here. [uncertain]
• Nařízení vlády č. 552/2025 Sb., issued 10 December 2025 and effective 1 January 2026, sets: who may prescribe and administer (specialist in psychiatry, or special qualification in medical psychotherapy); the failed-treatment precondition; the three indications; the duty to follow the clinical guideline; prescription formalities; limits on amounts and frequency (not reproduced here); a stopping rule when there is no clinically significant effect after a set number of administrations; and a minimum duration of special supervision that ends only when the physician confirms the effects have fully subsided. [source: NV 552/2025 Sb.]
• Related December 2025 instruments (Ministry of Health legislative newsletter 1/2026): NV 534/2025 Sb. amends the lists of addictive substances to allow therapeutic use. Vyhláška 545/2025 Sb. adds therapeutic psilocybin to the substances allowed in individually prepared medicines. Vyhláška 553/2025 Sb. sets the prescribing rules. [source: MZd newsletter]
• SÚKL (Státní ústav pro kontrolu léčiv): none of the texts drawn on defines a psilocybin-specific role for SÚKL. Pharmacovigilance reporting routes are not specified in the guideline. [uncertain]
• Outside the programme, psilocybin and other classical psychedelics remain controlled substances in Czechia. [source: epravo.cz; Blossom country page] Other jurisdictions are outside this entry and were not researched. [uncertain]
• Access status in 2026: On 23 March 2026, NUDZ (Národní ústav duševního zdraví) stated that treatment was not yet available, that there was no waiting list, that reimbursement conditions were still being negotiated, and that launch was expected in the second half of 2026. [source: NUDZ statement] As of 30 September 2026, a secondary tracker reported that no first patients, named authorised facilities or reimbursement had been confirmed, and noted a NUDZ project (June to December 2026) to secure therapeutic psilocybin for an observational study. [source: Blossom; secondary] Press in December 2025 expected initial capacity of a few dozen patients a year, mainly in Prague and Brno. [source: Expats.cz; secondary]

2. Framework

[source: Věstník guideline §§ 3–10, 14; NV 552/2025 Sb. §§ 2–4]

Indications (all require documented failure of, or intolerance to, registered treatments):

• (a) Depressive disorder associated with cancer, especially existential distress. The guideline cites the strongest evidence here.
• (b) Clinically severe depressive disorder without psychotic features. Requirements: an episode lasting at least six months, failure of at least two adequate antidepressant treatments (or the defined alternatives), and significant functional impairment. Maintenance use is permitted in responders and in remitters who relapse.
• (c) Sudden deterioration of another severe neuropsychiatric or mental disorder that seriously threatens life, where use is scientifically justified. Requirements: at least two failed standard treatments (one in very severe cases), at least six months' duration, and at least one randomised trial or prospective cohort supporting use. For addiction, only abstinent patients in residential or fractional treatment who have had a previous failed residential treatment qualify.
• The indicating psychiatrist records the supporting evidence both in the medical record and in the consent form.

Team and roles

• Indicating physician (indikující lékař): psychiatrist. Diagnoses, decides indication and contraindications, prescribes, keeps documentation, owns integration and complications, and runs the one-month follow-up.
• Supervising physician (lékař zajišťující zvláštní dohled): psychiatrist, or a palliative-care physician or a physician with the special qualification in medical psychotherapy, in either case with PAP postgraduate training. A doctor who has finished the psychiatry core may serve under supervision, with a qualified expert reachable within five minutes. Responsible for medical monitoring, acute interventions, discharge and the session record. Need not be in the room continuously.
• Main accompanying therapist (hlavní provázející terapeut): psychiatrist, physician with medical-psychotherapy qualification, or clinical psychologist. Must hold an approved comprehensive psychotherapy training for healthcare and PAP postgraduate training. Health psychologists and physicians may serve under direct supervision.
• Second accompanying therapist: a healthcare worker (e.g. addictologist, nurse) with completed comprehensive psychotherapy training. Trainees may serve under direct supervision of a qualified main therapist.
• Two-therapist rule: the guideline lists the therapist pair as the minimum staffing standard, but elsewhere calls pair work "recommended". It also requires at least one accompanying therapist with the patient throughout. This is internally inconsistent. Plan for two therapists, with at least one always in the room. [uncertain] The phrase "two specialist therapists" overstates it: the second therapist need not be a psychiatrist or psychologist.

Training and licensing of therapists

• PAP postgraduate programme: at least six months and at least 100 hours of theory and practice, plus a supervision block and supervised case work. It ends with a competency check.
• Programme guarantor: psychiatrist or clinical psychologist with at least five years of PAP or ketamine-assisted psychotherapy (KAP) practice, at least 50 sessions and at least 30 hours of supervision.
• Five-year transitional provisions recognise prior PAP, KAP or clinical-trial experience. Main therapists need at least 30 sessions in the last 36 months, or 50 at any time. Supervising physicians need set role-specific session counts. Physicians also complete short gap modules on legislation, safety and pharmacovigilance, and SOPs. External courses are recognised only if they meet the hour, content and supervision criteria.
• Facility: a Ministry permit where § 3(3) requires one, internal SOPs, a defibrillator, staff trained in basic life support, and access to emergency services.

Phases

Exclusion criteria published by the guideline (described qualitatively; thresholds and washout periods not reproduced):

• Absolute: psychotic disorder in the patient or a first-degree relative (including past history); bipolar I disorder; active alcohol or other substance dependence (limited exceptions); pregnancy and breastfeeding; concurrent MAO inhibitors (washout needed); raised intracranial pressure; haemorrhagic stroke within a defined recovery period; uncontrolled hypertension; acute heart failure, recent myocardial infarction or other serious cardiovascular disease (serious arrhythmia, intracranial or aortic aneurysm); allergy to any component of the preparation; brain tumour, including metastases.
• Other contraindications and cautions: untreated hyperthyroidism; severe respiratory failure; history of seizures; any serious somatic illness where a marked rise in blood pressure is dangerous.
• Relative: medicines with 5-HT2A or D2 antagonist action (some antipsychotics and antidepressants), which need a washout; milder cardiovascular disease. Unstable cardiovascular or respiratory conditions need specialist consultation and possibly specialist presence during the session.
• Interactions (general): lithium carries a risk of confusion or seizures. Some antiepileptics and antimicrobials interact. Uncertain interactions should go to a toxicology centre. Medication changes are made by the psychiatrist, never by the psychotherapist.

3. Guiding principles

[source: Věstník guideline unless marked]

• Guideline-bound, lege artis care: following the clinical guideline is a legal precondition for administration (§ 4(5) of Act 372/2011 Sb.; NV 552/2025 Sb.). In practice: no improvised protocols, and every deviation is a legal problem as well as a clinical one.
• Last-line treatment: psilocybin comes only after registered treatments have failed or were not tolerated. In practice: document the treatment history fully before referring.
• Evidence-anchored indication: the indicating psychiatrist writes the evidence for the patient's indication into both the record and the consent. In practice: the patient hears why this treatment, for them, now.
• Safety through exclusion: contraindications are excluded systematically before treatment. In practice: a family history of psychosis or bipolar I is an absolute stop, however keen the patient is.
• The alliance is the foundation of safety: in practice, do not schedule the session until the patient trusts the accompanying team.
• Psychotherapy, not drug administration: the medicine is embedded in preparation, accompaniment and integration. Repeat use is linked to the psychotherapy process. In practice: the psychotherapy sessions are part of the treatment, not optional add-ons.
• Non-directive accompaniment: the guideline states the therapeutic approach is "nedirektivní". In practice: follow the patient's experience; do not steer content or interpret during the session.
• Openness to the experience, with help for difficulties: in practice, encourage the patient to go towards what arises and offer grounding when it becomes too much.
• Guard against worldview destabilisation: preparation reduces the risk of epistemic or worldview destabilisation. In practice: keep metaphysical conclusions open and lightly held, and do not endorse them as fact.
• Secular setting: the room should not primarily evoke a religious or spiritual context. In practice: no religious objects, and no ritual framing by staff.
• Continuous presence: at least one accompanying therapist is with the patient for the whole session. In practice: hand over in the room, never by leaving the patient alone.
• Clear medical and psychological roles: medical monitoring and drug decisions belong to the supervising physician; psychological support belongs to the therapists. In practice: therapists escalate concerns and do not make medical calls.
• Psychological support first: most psychological adverse effects need no medication, only support from trained staff. In practice: try presence, reassurance and grounding before escalating, unless there is danger.
• Discharge only when resolved and stable: in practice, no discharge while altered, psychotic, worse or suicidal. The patient goes home with an escort and does not drive for 24 hours.
• Continuity of care: the indicating psychiatrist owns integration and complications, and the patient returns to their usual specialist with a report. In practice: an outside therapist should be told when the handover happens and what it contains (with consent).
• Complete documentation: a full session record is kept for at least ten years. In practice: the therapists' observations go into the medical record.
• Voluntariness and understanding: consent must be understood, not only signed. In practice: check understanding by having the patient explain it back. [synthesis for the method]

4. Intervention inventory

Scope note: the guideline lists its components but does not script them. Every item below that the guideline names is tagged [source: Věstník guideline]. Step-by-step detail beyond what the guideline states is my clinical synthesis and is tagged [synthesis]. Example language is illustrative only. Medical procedures (vital signs, laboratory tests, pharmacological rescue) belong to physicians and are named here, not described technically. The guideline says the in-session techniques (anchoring, breathwork, relaxation and meditation, supportive touch, music work) are taught in the PAP postgraduate training, whose content is not described here. [uncertain]

4.1 Referral and indication check (outside psychotherapist or treating psychiatrist)

• Purpose / when: a client with treatment-resistant depression, cancer-related depression or existential distress, or another life-threatening deterioration asks about psilocybin, or you think they may qualify. [source: guideline § 3; NV 552/2025 § 2]
• Steps: (1) Check the indication category and duration against § 2. (2) List prior treatments with adequacy and outcome; the psychiatrist will need trials, durations and intolerance documented. (3) Screen informally for obvious exclusions (personal or first-degree family history of psychosis, bipolar I, active dependence, pregnancy, serious cardiovascular disease, brain tumour) so you do not raise false hope. (4) With consent, send a summary to the client's psychiatrist, who refers to an authorised provider. (5) Explain the realistic status: as of the 2026 sources, access was not yet routinely open, there were no waiting lists, and reimbursement was unresolved. Point the client to NUDZ updates. [source: NUDZ statement 23 March 2026; steps 1–4 synthesis]
• Example language (illustrative): "Czech law now allows this treatment, but only in specialist psychiatric settings, for people for whom approved treatments haven't worked. Let's put your treatment history together so your psychiatrist can judge whether you'd qualify."
• Watch for: the client hearing "legal" as meaning available, or as meaning legal outside clinics; pressure to minimise family psychiatric history; despair if ineligible (see 4.20).

4.2 Comprehensive psychiatric assessment (indicating psychiatrist)

• Purpose / when: before any commitment. Confirms diagnosis and indication, excludes psychiatric comorbidity and contraindications, reviews medication (which may be reduced or stopped by the psychiatrist), and checks pregnancy or plans for pregnancy. [source: guideline § 6]
• Steps: a structured diagnostic interview; treatment-history verification; personal and family history of psychosis and bipolar disorder; substance-use history; suicide risk assessment by current standard practice; medication and interaction review; documenting the evidence basis. [source: guideline §§ 3, 6; suicide assessment and interview method synthesis]
• Example language (illustrative): "I need to ask in detail about relatives with psychosis or bipolar disorder, because that's one of the firm safety limits of this treatment."
• Watch for: concealment driven by eagerness; latent hypomania; family history the client is unsure of (treat this as needing clarification, not as clearance). [synthesis]

4.3 Somatic and neurological screening (medical team)

• Purpose / when: after psychiatric eligibility. Excludes somatic contraindications. [source: guideline § 6]
• Steps (named only): somatic and neurological examination; recent ECG with an internist's report; recent blood tests (blood count, inflammatory marker, electrolytes, lipids, renal and thyroid function); specialist consultation where a somatic contraindication is suspected; exclusion of brain tumour or metastases in oncology patients; repeat if somatic status changes.
• Psychotherapist's role: none in carrying it out. Help the client understand why it is done and support any anxiety about the results. [synthesis]

4.4 Informed consent conversation

• Purpose / when: before preparation is completed; written consent is a precondition. [source: guideline § 7]
• Steps: cover (1) the intervention and course of treatment; (2) psilocybin and the evidence base; (3) why it is being used for this patient (the indication evidence); (4) how care is organised and the roles of each staff member, including who is present and the use of supportive touch [touch item synthesis]; (5) expected benefits and limits; (6) insurance and compensation for harm; (7) voluntariness and the right to withdraw; (8) the 24-hour driving ban. Check understanding before signing. [source: guideline § 7; teach-back method synthesis]
• Example language (illustrative): "Before you sign, could you tell me in your own words what will happen on the day and what the risks are?"
• Watch for: consent given out of desperation; unrealistic expectations; misunderstanding that a single session is a cure. [synthesis]

4.5 Preparation: goals, motivation and expectations

• Purpose / when: preparation session 1 and onward. At least two preparation sessions, at least 180 minutes in total. [source: guideline § 8]
• Steps: (1) Ask what the client hopes will change in daily life, not only in the session. (2) Explore motivation, including whether it is the client's own or under pressure from family. (3) Name expectations about what the experience will be like and correct overly fixed ones (a guaranteed mystical experience, instant cure). (4) Write down two or three goals linked to the clinical problem for use in integration. [steps synthesis]
• Example language (illustrative): "If this helped, what would be different on an ordinary Tuesday a month from now?"
• Watch for: goals framed only as the experience itself; a hidden wish to escape or die (assess suicide risk); rigid expectations. [synthesis]

4.6 Preparation: building the therapeutic alliance

• Purpose / when: throughout preparation. The guideline calls the alliance the basic prerequisite for safety. [source: guideline § 8]
• Steps: (1) Make sure the client meets both accompanying therapists before the session day if possible. (2) Ask about past experiences of trust, abandonment or control with helpers. (3) Agree how the client will signal needs when it is hard to speak. (4) Invite and repair small ruptures now ("Is there anything about how we work that doesn't fit?"). [steps synthesis]
• Example language (illustrative): "On the day you might not be able to explain much. Let's agree a simple way to tell us you need something."
• Watch for: compliance without trust; discomfort with one therapist (consider changing the team); a trauma history that makes lying down in front of others hard. [synthesis]

4.7 Preparation: psychoeducation on altered states, including difficult elements

• Purpose / when: preparation. The guideline requires education about possible altered states, including difficult elements. [source: guideline § 8]
• Steps: (1) Describe in neutral terms the range of possible perceptual, emotional, bodily and time-sense changes, and difficult states such as fear, confusion, grief or feeling one is dying or going mad. (2) Describe the expected physical effects the guideline lists in general terms (nausea, headache, raised heart rate and blood pressure, temporary unsteadiness). (3) Explain that difficult states are expected and usually pass, and that staff are trained to help. (4) Mention the rare persisting perceptual effects and flashbacks noted in the guideline. [source: guideline §§ 8, 11; teaching order synthesis]
• Example language (illustrative): "Fear can be part of it. If it comes, it doesn't mean something has gone wrong. We'll be right there."
• Watch for: catastrophic misreading of normal effects; a client who becomes more anxious with each detail (shorten it and focus on skills). [synthesis]

4.8 Preparation: psychological openness and protecting against worldview destabilisation

• Purpose / when: preparation. The guideline names both promoting openness and reducing the risk of epistemic or worldview destabilisation. [source: guideline § 8]
• Steps: (1) Encourage a stance of curiosity towards whatever comes up ("go towards it"). (2) Agree in advance that strong convictions arising in the session (about the nature of reality, life decisions, relationships) will be treated as material to explore in integration, not as instructions. (3) Ask the client to postpone major life decisions until after integration. [steps 1–3 synthesis]
• Example language (illustrative): "Very powerful certainties can come up. Let's agree to look at them together afterwards before acting on them."
• Watch for: pre-existing magical or conspiratorial thinking; a strong wish for a spiritual answer, which the secular frame does not provide (see principle on setting). [synthesis]

4.9 Preparation: body-based techniques for tension

• Purpose / when: the guideline lists body-based techniques for managing physical signs of uncertainty or tension; practise them in preparation so they are familiar on the day. [source: guideline § 8]
• Steps (synthesis; the guideline does not specify which techniques): (1) Teach slow, extended out-breaths and noticing contact with the mattress or floor. (2) Teach a brief scan that names where tension sits without trying to remove it. (3) Rehearse with the therapist's cue phrase that will be used on the day.
• Example language (illustrative): "Notice where your back meets the mattress... let the out-breath be a little longer."
• Watch for: breathing exercises that increase panic in people with a history of panic attacks (switch to external grounding through touch, sound or sight). [synthesis]

4.10 Preparation: orienting to inner images and feelings

• Purpose / when: the guideline lists building the ability to orient oneself to inner images and feelings. [source: guideline § 8]
• Steps (synthesis): (1) Short eyes-closed practice with music, noticing images, feelings and sensations without judging. (2) Practise reporting briefly in a few words. (3) Practise returning attention to the breath or body when overwhelmed, then turning back towards the material.
• Example language (illustrative): "Just notice what shows up. You don't have to understand it."
• Watch for: intrusive trauma memories during practice (pace it, stabilise, and tell the indicating psychiatrist). [synthesis]

4.11 Practical safety briefing

• Purpose / when: the final preparation session. [source: guideline §§ 8–9]
• Steps: (1) The client arranges an escort or organised transport home. (2) No driving or operating machinery for 24 hours. (3) Warn of possible poor sleep that night; the physician can provide sleep medication if needed. (4) Explain the pre-session checks done on the day (vital signs, pregnancy test where relevant, urine drug screen, mental state check) and that a positive drug screen or emerging psychotic symptoms can lead to postponement. (5) The psychiatrist reviews legally used substances (cannabis, CBD, opioids, benzodiazepines). [source: guideline §§ 8, 9.1; order synthesis]
• Watch for: a missing escort (postpone); undisclosed substance use. [synthesis]

4.12 Preparing the setting

• Purpose / when: before the session day. [source: guideline § 9.2]
• Steps: a calm, aesthetically pleasing room with few distractions, a bed, music and soft light; no religious objects or primarily religious or spiritual framing; emergency equipment (defibrillator) available; SOPs and emergency contacts at hand. [source: guideline §§ 9.2, 12; layout details synthesis]
• Watch for: staff bringing personal spiritual objects or rituals into the room (this conflicts with the guideline). [synthesis]

4.13 Non-directive accompaniment during the session

• Purpose / when: the whole session. The guideline states the approach is non-directive, with the therapist supporting the patient to open up to the experience and helping them manage difficulties. [source: guideline § 9.3]
• Steps (synthesis): (1) Sit within the client's view and at a steady distance, and keep at least one therapist present at all times. (2) Speak little: brief check-ins only when the client signals or appears distressed. (3) Reflect rather than interpret; do not introduce themes. (4) Note observations for the record and for integration. (5) Change over between the two therapists only inside the room.
• Example language (illustrative): "I'm here." / "Can you let it be there for a moment?" / "You don't have to do anything with it."
• Watch for: therapist urges to guide or interpret; the client seeking reassurance repeatedly (offer steady presence instead of explanations); signs that need medical escalation (see 4.19). [synthesis]

4.14 Anchoring

• Purpose / when: when the client loses orientation or feels overwhelmed. Named in the guideline; the method is not described. [source: guideline § 9.3]
• Steps (synthesis): (1) Use the anchor agreed in preparation: the therapist's voice, a hand on the forearm if consented, or attention to the breath or the mattress. (2) Name time and place briefly. (3) Once steadier, invite the client to turn back towards the experience.
• Example language (illustrative): "You're in the clinic, I'm right here, and this will pass. Feel your back on the bed."
• Watch for: anchoring used to shut the experience down too early; it should restore enough safety for the client to continue. [synthesis]

4.15 Breathwork (in session)

• Purpose / when: to reduce tension and panic. Named in the guideline. [source: guideline § 9.3]
• Steps (synthesis): gentle, calming breathing only (for example a slower exhale) cued by the therapist. No hyperventilation-type or activating breathwork; that is my caution, not a guideline statement. Stop if breathing increases distress.
• Example language (illustrative): "Breathe out slowly with me... and again."
• Watch for: breath-holding, hyperventilation or tingling (switch to external anchors and tell the physician). [synthesis]

4.16 Relaxation and meditation techniques

• Purpose / when: named in the guideline for helping the patient manage difficulties. [source: guideline § 9.3]
• Steps (synthesis): use only techniques the client practised in preparation (body scan, open awareness, a brief phrase of acceptance). Offer them as options, not instructions, to stay non-directive.
• Watch for: meditation instructions that heighten depersonalisation in some clients; if so, move to concrete sensory anchors. [synthesis]

4.17 Supportive touch (podpůrný dotyk)

• Purpose / when: the guideline lists supportive touch among the accompanying techniques. It gives no detailed touch policy. [source: guideline § 9.3; gap noted]
• Steps (synthesis; check the provider's SOP): (1) In preparation, agree what kind of touch is acceptable (for example hand-holding or a hand on the shoulder or forearm), where, and the signals for yes and stop; record this in the file. (2) In session, offer touch verbally before giving it, and respect the agreement made while sober over requests made in the altered state that go beyond it. (3) Use non-sexual, non-intimate touch only, with both therapists aware. (4) Revisit how the touch was experienced in integration.
• Example language (illustrative): "Would it help if I held your hand, as we agreed?"
• Watch for: clients with sexual trauma; transference intensified by the altered state; any boundary drift. Treat touch outside the agreement as a reportable incident. [synthesis]

4.18 Music

• Purpose / when: music is part of the recommended setting, and music work is in the training syllabus. [source: guideline §§ 5, 9.2]
• Steps (synthesis): a prepared, non-lyrical or low-lyric playlist; let the client try headphones and an eye mask in preparation; allow the client to remove either at any time; lower or pause the music when the client wants to talk.
• Watch for: music experienced as intrusive or manipulative; offer silence. [synthesis]

4.19 Managing difficult and adverse states in session

• Purpose / when: fear, confusion, agitation, nausea, distressing memories, or physical symptoms. [source: guideline §§ 11–12]
• Steps: (1) Most psychological reactions need no medication, only support from trained staff: presence, anchoring and calm breathing. (2) Tell the supervising physician about severe anxiety with agitation that does not respond to support, any psychotic features, suicidal statements, or physical warning signs. The physician decides on pharmacological or emergency measures. (3) Physical emergencies follow the facility SOP (cardiology consultation, ambulance transfer, resuscitation). (4) A reaction lasting beyond the period the guideline defines leads to acute admission to a closed ward. (5) Everything is documented. [source: guideline §§ 11–12, 14; step order synthesis]
• Example language (illustrative): "This is the hard part we talked about. You're safe, the doctor is close by, and I'm staying with you."
• Watch for: self-endangering movement (make sure the room is safe); strong urges to leave (stay with the client and call the physician). [synthesis]

4.20 End of session, discharge and escort home

• Purpose / when: after the effects subside. [source: guideline §§ 9.3–9.5; NV 552/2025 § 4]
• Steps: (1) Special supervision lasts at least the regulated minimum and until the physician confirms the effects have fully subsided. (2) The physician checks vital signs and mental state and excludes persistent intoxication, emerging psychotic symptoms, worsening, and especially suicidal ideation. (3) The therapists give a brief, non-interpretive closing (synthesis). (4) The patient is handed to the escort or transport, reminded about driving and sleep, and given an emergency contact (contact synthesis). (5) The resolution is recorded in the medical record.
• Example language (illustrative): "You don't need to make sense of it today. We'll go through it together in a few days."
• Watch for: apparent calm masking distress; elation driving plans to act on new insights straight away. [synthesis]

4.21 Integration session 1 (within days)

• Purpose / when: reflect on the experience, help the client understand and reorient, ensure continuity of care, and prevent destabilisation. Two sessions of about 60–90 minutes each. [source: guideline § 10]
• Steps (synthesis): (1) Check current mental state, sleep and suicidality. (2) Invite a free account of the experience; the therapist adds observations. (3) Separate the client's account of what happened from the meaning they are making of it. (4) Note emotionally charged themes without rushing to conclusions. (5) Return to the goals set in preparation.
• Example language (illustrative): "What stays with you most? ... And what do you make of it now?"
• Watch for: a destabilised sense of reality, persisting perceptual changes, emerging hypomania or psychotic features, distress about "failed" or frightening sessions. Escalate to the indicating psychiatrist. [source for escalation: guideline § 10.1]

4.22 Integration session 2 (within about ten days)

• Purpose / when: link the experience to the clinical problem and attitudes, and plan next steps. [source: guideline § 10]
• Steps (synthesis): (1) Ask which insights or changes are showing in daily life. (2) Translate them into concrete behavioural or relational steps. (3) Plan how ongoing psychotherapy will carry this forward. (4) Revisit how the client experienced touch, the team and the music. (5) Agree what goes into the handover report.
• Example language (illustrative): "If that insight were true for the next month, what would you do differently this week?"
• Watch for: idealising the experience or the team; disappointment if nothing "happened"; the stopping rule and repeat-treatment questions (these go to the psychiatrist). [synthesis]

4.23 One-month follow-up, final report and handover

• Purpose / when: after integration. [source: guideline § 10.1]
• Steps: weekly contact (in person or by telephone) by the indicating psychiatrist, or in exceptional cases a qualified team member, for one month or more often if needed. Return to the original outpatient specialist no earlier than one month after the session, with a detailed medical report covering the course of treatment, therapeutic goals and recommendations.
• Watch for: delayed deterioration; a gap in care at handover (synthesis). The receiving psychotherapist should request the report with the client's consent. [synthesis]

4.24 Documentation

• Purpose / when: every session. [source: guideline § 14]
• Steps: record the indication and justification, administration details (kept by the physician), vital signs at each monitoring point, the course of the session, adverse effects, interventions, the final assessment and the end of supervision. Keep the record for at least ten years. Therapists should also record touch and agreed boundaries (synthesis).

4.25 Repeat-treatment decision (psychiatrist)

• Purpose / when: when the clinical effect is judged to be waning and relapse risk is evident, or as maintenance in recurrent depression or chronic conditions within the indications. [source: guideline § 10; NV 552/2025 § 3]
• Steps: the psychiatrist checks the regulatory limits and the stopping rule (no clinically significant effect after a set number of administrations ends treatment), repeats the eligibility checks, and links the repeat to the ongoing psychotherapy. Each repeat has its own preparation and integration (synthesis).

4.26 Outside psychotherapist: liaison during programme treatment

• Purpose / when: your client enters an authorised programme. [synthesis]
• Steps: (1) With written consent, share relevant history (trauma, dissociation, suicidality). (2) Agree with the programme team whether you continue sessions during preparation and integration, to avoid two parallel integration processes. (3) Pause exposure-type or destabilising work in the period around the session. (4) Request the final report and pick up the agreed recommendations.
• Example language (illustrative): "Let's agree with the clinic team who you'll talk to about the session, so you don't get two different readings of it."

4.27 Harm reduction and integration support for clients using psilocybin outside the programme

• Purpose / when: a client has used, or plans to use, psilocybin outside the legal route. Outside the programme it remains a controlled substance in Czechia. [source: epravo.cz; Blossom] The clinician does not facilitate, source or supervise use. [synthesis]
• Steps (synthesis): (1) Assess without judgement: psychiatric and family history (psychosis, bipolar I), cardiovascular history, pregnancy, and current medication, especially MAO inhibitors, lithium, antipsychotics and other psychoactive medicines, which the guideline treats as contraindications or cautions. (2) Explain in general terms why these are risks, and that the guideline excludes such people even in medical settings. (3) Advise against using if any exclusion applies, and against combining substances. (4) Safety-plan for crisis: emergency contacts, and when to go to emergency services. (5) Consider referral to the psychiatrist and to the legal route if the client might be eligible. (6) Offer integration of past experiences using 4.21–4.22 methods, and screen for persisting perceptual effects, destabilisation and suicidality. (7) Record discussions factually and know your confidentiality limits.
• Example language (illustrative): "I won't help arrange it, but I do want you safe. Can we go through the things that make it risky for you in particular?"
• Watch for: psychotic or manic symptoms; persisting perceptual disturbance (guideline § 12.3 options: abstinence, psychoeducation, lifestyle advice, CBT, possibly EMDR); unregulated "retreat" or underground offers. [source for § 12.3: guideline]

4.28 Supporting clients who are ineligible or waiting

• Purpose / when: a client is excluded or faces delay (in 2026 access was not yet routinely open). [source: NUDZ statement; Blossom]
• Steps (synthesis): acknowledge the disappointment; assess suicide risk; review other evidence-based options with the psychiatrist (other treatments for treatment-resistant depression, including trials); discourage illegal use as a substitute and use 4.27 if the client is determined to go ahead.
• Example language (illustrative): "Being excluded is about your safety, not about whether you deserve help. Let's look at what else is available."

5. Handling problems

The guideline covers adverse effects, persisting effects and continuity of care. Most process problems below are not addressed in it and are marked [synthesis].

• Stuck in preparation (alliance not forming, expectations stay rigid): do not schedule the session. Add preparation sessions beyond the minimum, change the therapist pair if the fit is poor, and revisit motivation. The guideline sets minimums, not maximums. [synthesis; minimum: guideline § 8]
• Resistance or ambivalence about the session itself: treat ambivalence as information. Remind the client that participation is voluntary and they can withdraw at any point, including on the day. Explore fears in concrete terms (losing control, being seen, dying). [voluntariness: guideline § 7; rest synthesis]
• Overwhelm during the session: use psychological support first (presence, anchoring, calm breathing, supportive touch if agreed). Escalate to the supervising physician for agitation that does not respond, psychotic features, suicidality or physical warning signs. The physician decides on medication. A reaction lasting beyond the period the guideline defines leads to admission to a closed ward. [source: guideline §§ 12.1, 9.4]
• Overwhelm after the session (destabilisation, insomnia, anxiety, depersonalisation): contact the indicating psychiatrist, who is responsible for complications, including psychological decompensation. Bring the integration session forward, increase follow-up frequency, and assess suicide risk. [source: guideline § 10.1; actions partly synthesis]
• Persisting perceptual effects or flashbacks (HPPD): the guideline says there is no evidence-based treatment. It lists non-drug approaches (abstinence, psychoeducation, lifestyle advice, CBT, possibly EMDR) and calls drug options experimental. [source: guideline § 12.3] Reassure the client that the symptom is recognised, reduce stimulants and sleep loss, and refer back to the psychiatrist. [synthesis]
• Suicidality at any point: follow current standard risk assessment and safety planning. At discharge the guideline specifically requires suicidal ideation to be excluded. If it appears afterwards, contact the indicating psychiatrist the same day and use crisis services. [source: guideline § 9.5; rest synthesis]
• Non-adherence (undisclosed substance use, medication changes made alone, no escort, missed integration): a positive drug screen or emerging psychotic symptoms on the day leads to postponement. Without an escort, the session does not take place. Missed integration should be followed up actively by the team. The psychiatrist alone decides medication changes; tell clients not to stop psychiatric medication on their own to qualify. [source: guideline §§ 9.1, 9.5; rest synthesis]
• Ruptures with the team (felt abandoned, over-controlled, touch experienced as wrong): name and explore the rupture in integration, take responsibility for the therapist's part, and document it. Report any touch outside the agreed limits through the provider's incident process. Offer a different therapist for further work. [synthesis]
• A "nothing happened" or disappointing session: normalise it and look for subtle changes. Explain that repeat decisions are made by the psychiatrist within regulatory limits, and that the stopping rule ends treatment after a set number of administrations without clinically significant effect. [stopping rule: NV 552/2025 § 3; rest synthesis]
• Overvaluing the experience (grandiosity, mission, sudden life decisions): use the pre-agreed postponement of major decisions. Screen for hypomania and tell the psychiatrist if present. [synthesis; destabilisation aim: guideline § 8]
• Spiritual or religious interpretations: the setting is deliberately secular. Explore the client's meanings respectfully as their own, without endorsing or debunking them. Refer to the client's own faith community or spiritual adviser if they want that. [setting: guideline § 9.2; rest synthesis]
• Adverse-event reporting: the guideline requires adverse effects to be monitored, documented and reported, and pharmacovigilance is a training block. It does not name the reporting route. In Czech practice, suspected adverse reactions to medicines are generally reported to SÚKL, but a psilocybin-specific route is not confirmed. Check the provider's SOP. [source: guideline §§ 5, 11, 14; SÚKL route uncertain]
• Client asks you to source psilocybin, recommend a retreat or "sit" for them: decline clearly, and explain the legal status and the clinical reasons (the guideline's exclusions and medical monitoring). Move to the harm-reduction and integration role in 4.27. Do not join any session outside the legal route. [synthesis; status: epravo.cz]
• Client distressed by lack of access in 2026: give accurate status (in 2026 the legal basis was in force but routine access and reimbursement were pending) and work on the alternatives in 4.28. [source: NUDZ; Blossom]
• Team-level difficulties (staffing short of two therapists, a trainee without supervision, the physician unavailable): the guideline's minimum standards and supervision rules apply. Postpone the session rather than run it below standard. [source: guideline § 4 roles; decision synthesis]

Sources

Sources:

• Klinický doporučený postup pro asistovanou psychoterapii psilocybinem pro léčebné použití (PS ČLS JEP, ČNPS; Věstník MZd částka 21/2025) (primary)
• Nařízení vlády č. 552/2025 Sb. (primary)
• Zákon č. 167/1998 Sb., consolidated text as of 1 January 2026 (Ministerstvo zdravotnictví) (primary; text before § 33l)
• Ministerstvo zdravotnictví, Legislativní newsletter 1/2026 (primary)
• Úrad vlády, Odbor protidrogové politiky: Dekriminalizace drogových trestných činů pokračuje (11 July 2025) (primary)
• NUDZ: Official Statement on the Availability of Psilocybin Treatment (23 March 2026) (primary)
• Jedličková K., Právní aspekty terapie psychedeliky, EPRAVO.CZ (2026) (secondary)
• Medical use of magic mushrooms to become legal in Czechia from 2026, Expats.cz (6 December 2025) (secondary)
• Blossom: Psychedelic Research and Access in Czechia (updated 30 September 2026) (secondary)

Legal instruments cited (not drawn on in full): Act No. 270/2025 Sb.; § 33l of Act 167/1998 Sb.; Act No. 378/2007 Sb. § 79a; Act No. 372/2011 Sb. § 4(5); NV 534/2025 Sb.; Vyhláška 545/2025 Sb.; Vyhláška 553/2025 Sb. [uncertain where described only via other sources]